Clinical Scorecard: Initial Assessment of MedSigLIP in Thyroid Cytology: A Comparative Benchmark with Frozen Encoders Versus ImageNet-Pretrained Models

At a Glance

Key Highlights

• EfficientNet achieved highest macro-F1 score (0.845), closely followed by MedSigLIP (0.836); difference not statistically significant after correction.
• MedSigLIP demonstrated superior calibration (lowest Expected Calibration Error of 0.025) and highest recall for Bethesda V (Suspicious) cases (0.808).
• Encoder selection should consider both discrimination and safety metrics, especially calibration and sensitivity for borderline Bethesda V cases, to support triage and expert review.

Guideline-Based Recommendations

Diagnosis

• Use FNAB cytology classified by Bethesda System for initial thyroid nodule risk stratification.
• Recognize diagnostic uncertainty and interobserver variability especially in Bethesda V (Suspicious) category.

Management

• Consider molecular testing or diagnostic lobectomy for indeterminate or suspicious Bethesda categories.
• Incorporate AI-based decision support models with well-calibrated outputs to assist in borderline case triage.

Monitoring & Follow-up

• Monitor model calibration and sensitivity particularly for Bethesda V cases to reduce overconfident misclassification.
• Validate AI model performance prospectively in real-world clinical triage workflows.

Risks

• Be aware of staining variability, scanner heterogeneity, and domain shift that may affect AI model generalization.
• Avoid relying solely on aggregate accuracy; consider calibration and class-wise sensitivity to mitigate misclassification risks.

Patient & Prescribing Data

Patients with thyroid nodules undergoing FNAB cytology classified into Bethesda II, V, and VI categories.

AI models like MedSigLIP may improve sensitivity and reliability in identifying suspicious (Bethesda V) nodules, potentially guiding selective expert review and reducing unnecessary procedures.

Clinical Best Practices

• Employ standardized Bethesda System reporting for FNAB cytology to improve communication and risk stratification.
• Use AI models with demonstrated calibration and sensitivity benefits for borderline categories to support clinical decision-making.
• Interpret AI predictions in conjunction with clinical and pathological findings, especially for indeterminate or suspicious cases.
• Prospectively validate AI tools in diverse clinical settings to ensure robustness against domain shifts and variability.

References

• Bethesda System for Reporting Thyroid Cytopathology
• MedSigLIP Medical Image-Text Pretraining
• Thyroid FNAB Cytology and AI Applications